Subclinical rejection and sirolimus associated edema in renal allograft recipients [1]

Transplant International

Volumn 20, Issue 7, 2007, Pages 636-639

  Rico, Jorge ^a   Cruzado, Josep M ^b   Bestard, Oriol ^b   Duarte, Verónica ^b   Rama, Inés ^b   Gomà, Montse ^b   Torras, Joan ^b   Grinyó, Josep M ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; DIURETIC AGENT; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; CASE REPORT; DISEASE COURSE; DOPPLER ECHOGRAPHY; EDEMA; FEMALE; HAND; HAND EDEMA; HEART FAILURE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY ALLOGRAFT REJECTION; LEG; LEG EDEMA; LETTER; MALE; PRIORITY JOURNAL; VEIN THROMBOSIS;

ADULT; AGED; EDEMA; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEG; MALE; SIROLIMUS;

EID: 34249904673     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00488.x     Document Type: Letter

References (14)

1. Meier-Kriesche HU, Steffen BJ, Chu AH, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004 4 : 2058.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005 5 : 2273.
3. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006 6 : 1991.
4. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving Sirolimus-Based Therapy. Transplantation 2005 79 : 476.
5. Warino L, Libecco J. Cutaneous effects of sirolimus in renal transplant recipients. J Drugs Dermatol 2006 5 : 273.
6. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005 5 : 2521.
7. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999 68 : 1526.
8. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997 64 : 436.
9. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004 78 : 264.
10. McGuire BM, Julian BA, Bynon JS Jr., et al. Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006 144 : 735.
11. Kaplan MJ, Ellis CN, Bata-Csorgo Z, Kaplan RS, Endres JL, Fox DA. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 1999 135 : 553.
12. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001 145 : 438.
13. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994 57 : 208.
14. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004 78 : 242.